n(4)-hydroxycytidine has been researched along with GRL-0617 in 1 studies
| Studies (n(4)-hydroxycytidine) | Trials (n(4)-hydroxycytidine) | Recent Studies (post-2010) (n(4)-hydroxycytidine) | Studies (GRL-0617) | Trials (GRL-0617) | Recent Studies (post-2010) (GRL-0617) |
|---|---|---|---|---|---|
| 42 | 1 | 32 | 13 | 0 | 12 |
| Protein | Taxonomy | n(4)-hydroxycytidine (IC50) | GRL-0617 (IC50) |
|---|---|---|---|
| Spike glycoprotein | Betacoronavirus England 1 | 0.6 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 0.6 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 0.6 | |
| Procathepsin L | Homo sapiens (human) | 0.6 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 0.6 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 0.6 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 1.1567 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.1191 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 0.6 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V | 1 |
1 review(s) available for n(4)-hydroxycytidine and GRL-0617
| Article | Year |
|---|---|
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |